HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC:NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Following its 2025 launch and early-stage growth, Neutra Life Sciences has proven its operational excellence with multiple clinical trial. Since its formation, Neutra Life Sciences has built the operational infrastructure required to support a sustainable, scalable site network, including standardized site operating procedures, an expanding investigator base, and a consistent track record of regulatory-compliant trial execution. This foundation has allowed the subsidiary to move from an early-growth phase into a stable operating model capable of supporting a broader, more diverse clinical trial portfolio.
Read more at globenewswire.comNeutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Ai%20chip%20by%20Quality%20Stock%20Arts%20via%20Shutterstock.jpg)
/A%20close-up%20of%20a%20SpaceX%20sign%20by%20Sundry%20Photography%20via%20Adobe%20Stock.jpeg)